Open house Risperidone rebate agreements
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.
For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of the pharmaceutical product Risperidone in the form of powder and solvent for injection solution (ATC N05AX08)
- Conclusion of a non-exclusive rebate agreement with AOK Bayern
Show full summary
This is an open-house model (not a standard procurement) by AOK Bayern for non-exclusive rebate agreements on Risperidone (powder and solvent for injection solution, ATC N05AX08). Any interested pharmaceutical company that meets the eligibility criteria can join. The agreement runs from 1 June 2025 to 31 May 2027. There is no competitive selection; contracts are concluded with all qualified suppliers. No estimated contract value is provided.
Risks
No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.
For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible to participate.
Administrative
- Submission of a signed self-declaration of reliability.
- Submission of the signed contract and annex (list of medicines subject to the agreement).
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Risperidone rebate agreements
Non-exclusive rebate agreement for Risperidone in the form of powder and solvent for injection solution. All interested pharmaceutical companies that meet the eligibility criteria can participate.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 249452-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.
For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications